ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced
Open access · greenAbstract read
In one paragraph
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
12.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- [Clinical Practice Guidelines for the Management of Brain Metastases from Non-small Cell Lung Cancer with Actionable Gene Alterations in China (2025 Edition)].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Guideline
- Comparative analysis of first-generation epidermal growth factor receptor inhibitors combined with chemotherapy versus third-generation epidermal growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- CNS Protective Effect of Selpercatinib in First-LineJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Brain metastasis: Opportunities for novel therapies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- Clinical implications of PD-L1 expression in oncogene-driven NSCLC: Differential responses to targeted agents and immune checkpoint inhibitors.International journal of cancer · 2026Article
- Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non-Small Cell Lung Cancer.Cancer research communications · 2026Article
- Comparative Efficacy and Safety of First-Line Immune Checkpoint Inhibitors Plus Chemotherapy with or Without Bevacizumab in Advanced Non-Squamous Non-Small Cell Lung Carcinoma.Current oncology (Toronto, Ont.) · 2026Article
- Clinical Outcomes of Different Generation EGFR TKIs in Susceptible EGFR-Mutated Advanced Nonsmall-Cell Lung Cancer.The Kaohsiung journal of medical sciences · 2026Article
- First Line and Treatment Sequencing in EGFR-Mutated Metastatic NSCLC: What is Right for Which Patient?Drugs · 2026Review
- SOS1 inhibition suppresses the emergence of osimertinib resistance to generate a durable response inScience signaling · 2025Article
- The promise of ctDNA-based, molecularly-driven early switch therapy from PADA-1 to SERENA-6.Breast cancer research and treatment · 2025Review
- Update on the Treatment of Non-Small Cell Lung Carcinoma (NSCLC).Journal of clinical medicine · 2025Review
- Real-World Outcomes of T790M Mutation Testing and Sequential Osimertinib in EGFR-Positive Advanced Non-small Cell Lung Cancer: A Revisited Strategy.Targeted oncology · 2025Article
- The curse of blood-brain barrier and blood-tumor barrier in malignant brain tumor treatment.International journal of clinical oncology · 2025Review
- Integration of Liquid Biopsy for Optimal Management of Non-small Cell Lung Cancer.Tuberculosis and respiratory diseases · 2025Article
- Percutaneous Lung Biopsy: Evidence-Based Techniques to Reduce Complications.Seminars in interventional radiology · 2025Review
- The APPLE's core question-upfront osimertinib versus the sequential approach forJournal of thoracic disease · 2025Article
- Emerging Therapies for Brain Metastases in NSCLC, Breast Cancer, and Melanoma: A Critical Review.Current neurology and neuroscience reports · 2024Review
- Optimizing Treatment Strategies forCancers · 2024Article
- Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC.ESMO real world data and digital oncology · 2024Article
Corrections and comments
- Commented on by
Authors and funding
22 authors at 18 institutions in 6 countries.
Jordi RemonParis-Saclay University, Institut Gustave Roussy, Villejuif, France.ORCID 0000-0002-9462-875X
Benjamin BesseParis-Saclay University, Institut Gustave Roussy, Villejuif, France.ORCID 0000-0001-5090-8189
Santiago Ponce AixHospital Universitario 12 De Octubre, Madrid, Spain.
Ana CallejoHospital Universitari Vall d'Hebron- Vall d'Hebron Institut Oncologia, Barcelona, Spain.ORCID 0000-0003-2556-8412
Kamal Al-RabiKing Hussein Cancer Center, Amman, Jordan.ORCID 0009-0007-7492-6374
Reyes BernabeUniversity Hospital Virgen del Rocio, Sevilla, Spain.
Laurent GreillierAix Marseille University, Assitance Publique-Hôpitaux de Marseille (APHM), Marseille, France.ORCID 0000-0002-5807-9503
Margarita MajemHospital De La Santa Creu I Sant Pau, Barcelona, Spain.
Noemi ReguartHospital Clinic Universitari de Barcelona, IDIBAPS, Barcelona, Spain.ORCID 0000-0001-8190-499X
Isabelle MonnetCentre Hospitalier Intercommunal De Creteil, Creteil, France.
Sophie CousinInstitut Bergonie, Bordeaux, France.
Pilar GarridoHospital Universitario Ramon y Cajal, Madrid, Spain.ORCID 0000-0002-5899-6125
Gilles RobinetCHU de Brest, Brest, France.
Rosario Garcia CampeloUniversity Hospital A Coruna-Hospital Teresa Herrera, A Coruna, Spain.ORCID 0000-0002-5067-7533
Anne MadroszykInstitut Paoli-Calmettes, Marseille, France.
Julien MazièresCHU de Toulouse-Hopital Larrey, Toulouse, France.ORCID 0000-0002-5921-7613
Hubert CurcioCentre François Baclesse, CHU Côte de Nacre, Caen, France.ORCID 0000-0003-3428-506X
Bartosz WasągMedical University of Gdansk, Gdansk, Poland.ORCID 0000-0002-3634-7562
Yassin PretzenbacherEORTC Headquarters, Brussels, Belgium.
Fanny GrilletEORTC Headquarters, Brussels, Belgium.
Anne-Marie C DingemansErasmus Medical Center, Rotterdam, the Netherlands.ORCID 0000-0001-6105-182X
Rafal DziadziuszkoMedical University of Gdansk, Gdansk, Poland.
European Organisation for Research and Treatment of Cancer · BEGdańsk Medical University · PLUniversité Paris-Saclay · FRAix-Marseille Université · FRCentre Hospitalier Régional Universitaire de Brest · FRCentre Hospitalier Universitaire de Caen Normandie · FRCentre Hospitalier Universitaire de Toulouse · FRErasmus MC · NLHôpital Intercommunal de Créteil · FRHospital de Sant Pau · ESHospital Universitari de Vic · ESHospital Universitario 12 De Octubre · ESHospital Universitario Ramón y Cajal · ESHospital Universitario Virgen del Rocío · ESInstitut Bergonié · FRInstitut Paoli-Calmettes · FRKing Hussein Cancer Center · JOVall d'Hebron Hospital Universitari · ES
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AcrylamidesCarcinoma, Non-Small-Cell LungIndolesLung NeoplasmsPyrimidinesAniline CompoundsErbB ReceptorsGefitinibHumansMutationProtein Kinase InhibitorsAcrylamidesAniline CompoundsEGFR protein, humanErbB ReceptorsGefitinibIndolesosimertinibProtein Kinase InhibitorsPyrimidines
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.